GenMark Diagnostics, Inc. (GNMK) SVP Sells $12,888.06 in Stock

GenMark Diagnostics, Inc. (NASDAQ:GNMK) SVP Jennifer Anne Williams sold 2,719 shares of the firm’s stock in a transaction dated Monday, November 20th. The shares were sold at an average price of $4.74, for a total transaction of $12,888.06. Following the completion of the transaction, the senior vice president now directly owns 152,709 shares in the company, valued at $723,840.66. The sale was disclosed in a document filed with the SEC, which is available at this link.

Jennifer Anne Williams also recently made the following trade(s):

  • On Friday, September 15th, Jennifer Anne Williams sold 38,681 shares of GenMark Diagnostics stock. The shares were sold at an average price of $9.08, for a total transaction of $351,223.48.

Shares of GenMark Diagnostics, Inc. (GNMK) traded down $0.07 during midday trading on Friday, hitting $4.64. 334,300 shares of the stock were exchanged, compared to its average volume of 423,431. The company has a debt-to-equity ratio of 0.12, a current ratio of 2.97 and a quick ratio of 2.77. GenMark Diagnostics, Inc. has a fifty-two week low of $3.63 and a fifty-two week high of $13.67.

GenMark Diagnostics (NASDAQ:GNMK) last posted its earnings results on Thursday, November 2nd. The medical equipment provider reported ($0.28) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.26) by ($0.02). GenMark Diagnostics had a negative net margin of 116.76% and a negative return on equity of 100.33%. The company had revenue of $11.60 million during the quarter, compared to analyst estimates of $14.56 million. During the same quarter last year, the business posted ($0.27) EPS. The firm’s revenue for the quarter was up 7.4% on a year-over-year basis. sell-side analysts expect that GenMark Diagnostics, Inc. will post -1.17 EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “GenMark Diagnostics, Inc. (GNMK) SVP Sells $12,888.06 in Stock” was originally posted by Community Financial News and is owned by of Community Financial News. If you are viewing this story on another site, it was copied illegally and republished in violation of U.S. and international trademark & copyright legislation. The correct version of this story can be read at https://www.com-unik.info/2017/11/24/genmark-diagnostics-inc-gnmk-svp-sells-12888-06-in-stock.html.

GNMK has been the topic of a number of research reports. Cowen Inc reaffirmed an “outperform” rating and issued a $17.00 price target on shares of GenMark Diagnostics in a research note on Wednesday, August 2nd. Canaccord Genuity reaffirmed a “buy” rating and issued a $14.00 price target (down from $17.00) on shares of GenMark Diagnostics in a research note on Monday, August 7th. BidaskClub lowered shares of GenMark Diagnostics from a “hold” rating to a “sell” rating in a research note on Monday, August 14th. BTIG Research reissued a “buy” rating and issued a $13.00 target price on shares of GenMark Diagnostics in a research note on Thursday, August 31st. Finally, Needham & Company LLC reissued a “buy” rating and issued a $15.00 target price (down from $17.00) on shares of GenMark Diagnostics in a research note on Wednesday, September 13th. Two equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and five have given a buy rating to the company’s stock. The company has an average rating of “Hold” and an average target price of $11.80.

Institutional investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. increased its holdings in GenMark Diagnostics by 15.8% in the 2nd quarter. JPMorgan Chase & Co. now owns 4,097,767 shares of the medical equipment provider’s stock valued at $48,476,000 after purchasing an additional 559,629 shares during the last quarter. Federated Investors Inc. PA grew its stake in shares of GenMark Diagnostics by 62,991.5% in the second quarter. Federated Investors Inc. PA now owns 200,000 shares of the medical equipment provider’s stock worth $2,366,000 after acquiring an additional 199,683 shares in the last quarter. Marshall Wace North America L.P. lifted its position in shares of GenMark Diagnostics by 1,787.6% during the 2nd quarter. Marshall Wace North America L.P. now owns 544,020 shares of the medical equipment provider’s stock worth $6,528,000 after purchasing an additional 515,200 shares during the last quarter. Northpointe Capital LLC lifted its position in shares of GenMark Diagnostics by 24.4% during the 3rd quarter. Northpointe Capital LLC now owns 1,552,740 shares of the medical equipment provider’s stock worth $14,953,000 after purchasing an additional 304,232 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its position in shares of GenMark Diagnostics by 8.9% during the 2nd quarter. Bank of New York Mellon Corp now owns 223,163 shares of the medical equipment provider’s stock worth $2,641,000 after purchasing an additional 18,235 shares during the last quarter.

GenMark Diagnostics Company Profile

GenMark Diagnostics, Inc is a molecular diagnostics company. The Company is focused on developing and commercializing multiplex molecular tests that aid in the diagnosis of complex medical conditions. It develops and commercializes multiplex molecular tests based on its eSensor electrochemical detection technology.

Insider Buying and Selling by Quarter for GenMark Diagnostics (NASDAQ:GNMK)

What are top analysts saying about GenMark Diagnostics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for GenMark Diagnostics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit